STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients

Raghvendra M Srivastava,Soldano Ferrone,Hyun-Bae Jie,Robert L Ferris

doi:10.1186/2051-1426-1-s1-p175

Abstract

Meeting abstracts Squamous cell carcinoma of head and neck (HNSCC) cells express low HLA class I and antigen processing machinery (APM) components, such as transporter TAP-1/2, which is associated with the reduced sensitivity to cytotoxic T lymphocyte (CTL) mediated lysis. Epidermal growth factor

Highlights

STAT1 contributes to HLA class I upregulation and cytotoxic T lymphocyte (CTL) reactivity after anti-Epidermal growth factor receptor (EGFR) mAb cetuximab therapy in head and neck cancer patients
Squamous cell carcinoma of head and neck (HNSCC) cells express low HLA class I and antigen processing machinery (APM) components, such as transporter TAP-1/2, which is associated with the reduced sensitivity to cytotoxic T lymphocyte (CTL) mediated lysis
We show that cetuximab or EGFR knockdown enhanced expression of HLA class I antigens, which is associated with the EGFR expression level on HNSCC

Summary

Introduction

Squamous cell carcinoma of head and neck (HNSCC) cells express low HLA class I and antigen processing machinery (APM) components, such as transporter TAP-1/2, which is associated with the reduced sensitivity to cytotoxic T lymphocyte (CTL) mediated lysis. STAT1 contributes to HLA class I upregulation and CTL reactivity after anti-EGFR mAb cetuximab therapy in head and neck cancer patients Epidermal growth factor receptor (EGFR) is overexpressed in HNSCC and is associated with the poor prognosis.

Results

Conclusion